ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near London, England, GBR:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

London, England, United Kingdom and 71 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

London, United Kingdom and 210 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

London, United Kingdom and 123 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Active, not recruiting
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

London, United Kingdom and 262 other locations

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)

growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC).The study will compris...

Enrolling
Non-Small Cell Lung Cancer
Biological: BNT116
Biological: Bispecific antibody for PD-L1 and VEGF-A

Phase 1

BioNTech
BioNTech

London, United Kingdom and 44 other locations

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non...

Begins enrollment this month
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Drug: Pumitamig
Drug: Imzokitug

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

London, Greater London, United Kingdom and 70 other locations

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and P...

Enrolling
Lung Cancer, Non-Small Cell
Biological: Dostarlimab
Drug: Pemetrexed+ (carboplatin or cisplatin)

Phase 1, Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

London, United Kingdom

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small c ...

Active, not recruiting
Non-Small-Cell Lung Cancer
Drug: Amivantamab
Drug: Carboplatin

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Sutton, United Kingdom and 71 other locations

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells...

Enrolling
Non-Small Cell Lung Cancer
Drug: Osimertinib
Drug: Standard of Care

Phase 2, Phase 3

AbbVie
AbbVie

London, Greater London, United Kingdom and 109 other locations

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor c-...

Active, not recruiting
Lung Cancer, Non-Small Cell
Drug: Belrestotug
Drug: Pembrolizumab

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Middlesex, United Kingdom and 98 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems